GlaxoSmithKline plc (GSKN) — Cash Flow-to-Debt Ratio
GlaxoSmithKline plc (GSKN) has a Cash Flow-to-Debt Ratio of 0.05x as of September 2025, meaning its operating cash flow of MX$2.22 Billion could theoretically repay 0% of its total liabilities (MX$45.59 Billion) in one year. See financial agility of GlaxoSmithKline plc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
GlaxoSmithKline plc Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for GlaxoSmithKline plc across 12 annual periods. For the full cash flow conversion analysis, see GlaxoSmithKline plc (GSKN) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for GlaxoSmithKline plc (2013–2024)
Year-by-year debt coverage analysis for GlaxoSmithKline plc. Check cash flow quality index of GlaxoSmithKline plc to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (MXN) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.14x | MX$6.55 Billion | MX$46.38 Billion | ▲ +19.2% |
| 2023 | 0.12x | MX$5.48 Billion | MX$46.21 Billion | ▼ -19.9% |
| 2022 | 0.15x | MX$7.40 Billion | MX$50.05 Billion | ▲ +7.4% |
| 2021 | 0.14x | MX$7.95 Billion | MX$57.76 Billion | ▼ -2.8% |
| 2020 | 0.14x | MX$8.44 Billion | MX$59.62 Billion | ▲ +8.3% |
| 2019 | 0.13x | MX$8.02 Billion | MX$61.34 Billion | ▼ -15.5% |
| 2018 | 0.15x | MX$8.42 Billion | MX$54.39 Billion | ▲ +18.4% |
| 2017 | 0.13x | MX$6.92 Billion | MX$52.89 Billion | ▲ +8.9% |
| 2016 | 0.12x | MX$6.50 Billion | MX$54.12 Billion | ▲ +108.3% |
| 2015 | 0.06x | MX$2.57 Billion | MX$44.57 Billion | ▼ -60.2% |
| 2014 | 0.14x | MX$5.18 Billion | MX$35.72 Billion | ▼ -31.2% |
| 2013 | 0.21x | MX$7.22 Billion | MX$34.27 Billion | — |